Tumor-induced osteomalacia: A case report;Osteomalácia induzida por tumor: Relato de caso

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 53, Issue 3, 2009, Pages 378-382

  Romualdo Silva, Daniel Dutra ^a   Silva, Bárbara Campolina Carvalho ^a   Caetano, Cristiane Vasconcelos ^a   Tibúrcio, Angelica Maria Franca Paiva ^a   Nunes, Maurício Buzelin ^a   Chagas, Sérgio Almeida Pinheiro ^a   Polito, Elizandra Tomazela Laurenti ^a   Ferreira, Antônio Rodrigues ^a   Purisch, Saulo ^a  

^a Hospital Santa Casa de Belo Horizonte   (Brazil)

Author keywords

Growth factor fibroblasts; Hypophosphatemia; Hypophosphatemic rickets; Osteomalacia; Phosphorus metabolism disorder

Indexed keywords

EID: 68249137003     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/S0004-27302009000300014     Document Type: Article

References (18)

1. Filho HM, Castro LCG, Damiani D. Hypophosphatemic rickets and osteomalacia. Arq Bras Endocrinol Metabol. 2006;50(4):802-13.
2. Khosravi A, Cutler CM, Kelly MH, Chang R, Royal RE, Sherry RM, et al. Determination of the elimination half-life of fibroblast growth factor-23. J Clin Endocrinol Metab. 2007;92(6):2374-7.
3. Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, et al. Fibroblast Growth Factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Eng J Med. 2003;348(17):1656-63.
4. Yoshiko Y, Wang H, Minamizaki T, Ijuin C, Yamamoto R, Suemune S, et al. Mineralized tissue cells are a principal source of FGF23. Bone. 2007;40(6):1565-73.
5. Yamashita H, Yamazaki Y, Hasegawa H, Yamashita T, Fukumoto S, Shigematsu T, et al. Fibroblast Growth Factor 23 (FGF-23) in patients with transient hypoparathyroidism: Its important role in serum phosphate regulation. Endocr J. 2007;54(3):465-70.
6. Imel EA, Hui SL, Econs MJ. FGF23 concentrations vary with disease status in autosomal dominant hypophosphatemic rickets. J Bone Miner Res. 2007;22(4):520-6.
7. Murer H, Hernando N, Forster I, Biber J. Proximal tubular phosphate reabsorption: molecular mechanisms. Physiol Rev. 2000;80(4):1373-409.
8. Folpe AL, Fanburg-Smith JC, Billings SD, Bisceglia M, Bertoni F, Cho JY, et al. Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity. An analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol. 2004;28(1):1-30.
9. Jan de Beur SM. Tumor-induced osteomalacia. JAMA. 2005;294(10): 1260-7.
10. Kobayashi K, Imanishi Y, Koshiyama H, Miyauchi A, Wakasa K, Kawata T, et al. Expression of FGF23 is correlated with serum phosphate level in isolated fibrous dysplasia. Life Sci. 2006;78(20):2295-301.
11. Nelson AE, Bligh RC, Mirams M, Gill A, Au A, Clarkson A, et al. Clinical case seminar: Fibroblast growth factor 23: a new clinical marker for oncogenic osteomalacia. J Clin Endocrinol Metab. 2003;88(9):4088-94.
12. Liu S, Quarles LD. How fibroblast growth factor 23 works. J Am Soc Nephrol. 2007;18(6):1637-47.
13. Imel EA, Peacock M, Pitukcheewanont P, Heller HJ, Ward LM, Shulman D, et al. Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia. J Clin Endocrinol Metab. 2006;91(6):2055-61.
14. Carpenter TO. Oncogenic osteomalacia--a complex dance of factors. N Eng J Med. 2003;348(17):1705-8.
15. Moreira RO, Leal CT, Lacativa PG, Figueiredo JG, Lima MB, Farias LM. Hyperparathyroidism associated with hypophosphatemic osteomalacia: case report and review of the literature. Arq Bras Endocrinol Metab. 2006;50(1):150-5.
16. Cheung FMF, Ma L, Wu WC, Siu TH, Choi PT, Tai YP. Oncogenic osteomalacia associated with an occult phosphaturic mesenchymal tumour: clinico-radiologico-pathological correlation and ultrastructural studies. Hong Kong Med J. 2006;12(4):319-21.
17. Weidner N, Santa Cruz D. Phosphaturic mesenchymal tumors: a polymorphous group causing osteomalacia or rickets. Cancer. 1987;59(8):1442-54.
18. Takeuchi Y, Suzuki H, Ogura S, Imai R, Yamazaki Y, Yamashita T, et al. Venous sampling for fibroblast growth factor-23 confirms pre-operative diagnosis of tumor-induced osteomalacia. J Clin Endocrinol Metab. 2004;89(8):3979-82.